Axiom

Axiom is a private, pre-revenue AI/ML biotech company founded in 2015, focused on transforming preclinical drug safety assessment. The company has developed a proprietary technology platform that integrates a large dataset of molecular profiles with mechanistic AI models to predict and explain human drug toxicity, specifically targeting the high failure rate of drug candidates due to unexpected liver injury (DILI). Backed by notable venture capital firms, Axiom positions itself as a provider of 'translational intelligence' to biopharma companies, aiming to replace or augment traditional animal testing with more accurate, human-predictive models.

A proprietary AI platform that integrates a large-scale dataset of molecular experimental profiles linked to human outcomes with mechanistic reasoning models to predict and explain drug toxicity, specifically drug-induced liver injury (DILI).

Axiom competes in the broad AI-driven drug discovery space, with direct competitors including other startups focused on predictive toxicology (e.g., Recursion, Insilico Medicine's related efforts, Valo Health) and traditional preclinical CROs adopting AI. Its differentiation hinges on its claimed 'mechanistic reasoning' and proprietary dataset linking experiments to human outcomes.